Studiencode: Not applicable
| Institution: | Analysis Group, Inc. | Auftraggeber: | MERCK SHARP & DOHME LLC |
| Titel der NIS: | Real-World Evidence on Patient Characteristics, Neoadjuvant/Adjuvant Treatment and Rate of Recurrence and Survival in Patients with Muscle Invasive Bladder Cancer (MIBC) Receiving Radical Cystectomy in Europe: A Physician Panel-based Chart Review | ||
| Ziel der NIS: | The goal is to describe the patient journey, highlight unmet need, and evaluate the association of disease recurrence with overall survival (OS) among MIBC patients who planned for and/or received radical cystectomy with or without pelvic lymph node dissection (RC +/- PLND) as the primary/initial treatment. Data will be collected on patients who planned for and/or underwent RC +/- PLND between 01 January 2010 and 1 November 2023. |
||
| Ort der Durchführung: | multinational | ||
| Patientenanzahl insgesamt: | 800 | Anzahl Ärzte insgesamt: | 320 |
| Patientenanzahl in Deutschland: | ~338 | Ärzte in Deutschland: | ~135 |
| Anzeige am: | 15.08.2024 | Geplanter Beginn: | 01.10.2024 | Geplantes Ende: | 01.10.2025 |
| Arzneimittelbezeichnung | INN | Zulassungs-Nr. | ATC-Code | Substanzklasse |
|---|---|---|---|---|
| Not applicable | Not applicable |
| Art des Dokuments | |
|---|---|
| Beobachtungsplan, NIS 783 | pdf 535KB |
